TEMPEST THERAPEUTICS
Live / Applied — First extension granted (statement of use) (as of 20 Nov 2025)
What this means for you
Not registered yet, but its 26 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98717805
- Mark type
- Stylized text
- Filed
- 26 Aug 2024
- Published for opposition
- 25 Mar 2025
- Attorney of record
- Brandon P. Leahy
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; vaccines for human use
Owner
- Tempest Therapeutics, Inc., Brisbane, CA, US
- Tempest Therapeutics, Inc., Brisbane, CA, US
Prosecution history
- 21 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Nov 2025 — SOU EXTENSION 1 GRANTED
- 20 Nov 2025 — SOU EXTENSION 1 FILED
- 20 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 20 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Mar 2025 — PUBLISHED FOR OPPOSITION
- 19 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 04 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 04 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 04 Mar 2025 — EXAMINERS AMENDMENT E-MAILED
- 04 Mar 2025 — EXAMINERS AMENDMENT -WRITTEN
- 03 Mar 2025 — ASSIGNED TO EXAMINER
- 26 Aug 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED